3 results
Approved WMOPending
The purpose of this study is to show that the incidence of new thrombotic events during an additional 6 or 12 months of treatment with rivaroxaban is lower when compared to placebo and that the likely advantage of an extended effect is not offset by…
Approved WMOCompleted
To evaluate the difference in the post fat load non HDL after an oral fatload between bezafibrate and placebo in patients with FD using standard lipid-lowering therapy
Approved WMOCompleted
To evaluate the effect of bezafibrate in cholestatic pruritus.